Toni K. Choueiri, MD
The standard of care for patients with renal cell carcinoma (RCC) continues to change as novel therapies and combinations rapidly get approved, says Toni K. Choueiri, MD.
For example, the December 2017 FDA approval of cabozantinib (Cabometyx) was based off of practice-changing data from the phase II CABOSUN trial, in which the multikinase inhibitor reduced the risk of progression or death by 52% compared with sunitinib (Sutent). Additionally, the median progression-free survival was 8.6 months with cabozantinib versus 5.3 months for sunitinib (HR, 0.48; 95% CI, 0.31-0.74; P
... to read the full story